{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:45Z","timestamp":1787067645074,"version":"build-2736575974"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clon.2024.08.006","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T05:38:17Z","timestamp":1723527497000},"page":"103631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical Impact of Constitutional Genomic Testing on Current Breast Cancer Care"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1170-6810","authenticated-orcid":false,"given":"W.","family":"Cheah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1719-7255","authenticated-orcid":false,"given":"R.I.","family":"Cutress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9935-3169","authenticated-orcid":false,"given":"D.","family":"Eccles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8994-4056","authenticated-orcid":false,"given":"E.","family":"Copson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2024.08.006_bib1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10549-021-06478-z","article-title":"An overview of genetic services delivery for hereditary breast cancer","volume":"191","author":"Reid","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clon.2024.08.006_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2147\/CLEP.S206949","article-title":"A\u00a0systematic review of the international prevalence of BRCA mutation in breast cancer","volume":"11","author":"Armstrong","year":"2019","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.clon.2024.08.006_bib3","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1007\/s11033-022-07571-2","article-title":"Breast cancer in the era of precision medicine","volume":"49","author":"Sarhangi","year":"2022","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.clon.2024.08.006_bib4","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","article-title":"Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer","volume":"3","author":"Couch","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib5","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s10549-009-0565-0","article-title":"BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer","volume":"122","author":"Gorski","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clon.2024.08.006_bib7","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clon.2024.08.006_bib8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2024.08.006_bib9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/CCO.0b013e328359554e","article-title":"Next-generation sequencing in breast cancer: first take home messages","volume":"24","author":"Desmedt","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-023-02296-w","article-title":"Risk-reducing surgery for individuals with cancer-predisposing germline pathogenic variants and no personal cancer history: a review of current UK guidelines","author":"McCarthy","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2024.08.006_bib12","first-page":"66","article-title":"A\u00a0Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1","volume":"266","author":"Miki","year":"1994","journal-title":"Science (1979)"},{"key":"10.1016\/j.clon.2024.08.006_bib13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","article-title":"Identification of the breast cancer susceptibility gene BRCA2","volume":"378","author":"Wooster","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.clon.2024.08.006_bib14","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMra0802968","article-title":"Inherited Susceptibility to Common Cancers","volume":"359","author":"Foulkes","year":"2008","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2024.08.006_bib15","first-page":"2011","article-title":"Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study","volume":"59","author":"Armes","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.clon.2024.08.006_bib16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/00313020220147113","article-title":"The pathology of inherited breast cancer","volume":"34","author":"Armes","year":"2002","journal-title":"Pathology"},{"key":"10.1016\/j.clon.2024.08.006_bib17","article-title":"Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes","volume":"8","author":"Mavaddat","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib18","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1038\/modpathol.2010.37","article-title":"Pathology of hereditary breast cancer","volume":"23","author":"Da Silva","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clon.2024.08.006_bib19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10549-016-3697-z","article-title":"Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens","volume":"155","author":"Evans","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clon.2024.08.006_bib20","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N","article-title":"The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study","volume":"83","author":"Armes","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2024.08.006_bib21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/cjp2.155","article-title":"Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers","volume":"6","author":"McCrorie","year":"2020","journal-title":"J\u00a0Pathol Clin Res"},{"key":"10.1016\/j.clon.2024.08.006_bib22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1471-2407-8-155","article-title":"Penetrance estimates for BRCA1 and BRCA2based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast\/ovarian cancer quoted should reflect the cancer burden in the family","volume":"8","author":"Evans","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2024.08.006_bib23","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clon.2024.08.006_bib24","first-page":"741","article-title":"Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study","volume":"8","author":"Hopper","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clon.2024.08.006_bib25","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.clon.2024.08.006_bib26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10549-021-06104-y","article-title":"Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis","volume":"186","author":"Liu","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clon.2024.08.006_bib27","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/jnci\/djt134","article-title":"Prospective Observational Study of Breast Cancer Treatment Outcomes for UK Women Aged 18\u201340 Years at Diagnosis: The POSH Study","volume":"105","author":"Copson","year":"2013","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10.1016\/j.clon.2024.08.006_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","article-title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","volume":"19","author":"Copson","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-014-2890-1","article-title":"Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis","volume":"144","author":"Valachis","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clon.2024.08.006_bib30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/SLA.0000000000001930","article-title":"Local Recurrence and Breast Oncological Surgery in Young Women With Breast Cancer","volume":"266","author":"Maishman","year":"2017","journal-title":"Ann Surg"},{"key":"10.1016\/j.clon.2024.08.006_bib31","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1245\/s10434-022-11756-1","article-title":"Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy","volume":"29","author":"Shubeck","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-010-0894-z","article-title":"Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy","volume":"121","author":"Pierce","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clon.2024.08.006_bib33","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10.1016\/j.clon.2024.08.006_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.breast.2022.12.001","article-title":"Does mainstream BRCA testing affect surgical decision-making in newly-diagnosed breast cancer patients?","volume":"67","author":"Ain","year":"2023","journal-title":"The Breast"},{"key":"10.1016\/j.clon.2024.08.006_bib35","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41431-017-0057-3","article-title":"Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history","volume":"26","author":"Meiser","year":"2018","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.clon.2024.08.006_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib37","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clon.2024.08.006_bib38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.annonc.2022.01.009","article-title":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib39","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib40","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2024.08.006_bib41","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2024.08.006_bib42","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2024.08.006_bib43","series-title":"Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy","year":"2023"},{"key":"10.1016\/j.clon.2024.08.006_bib44","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/ijms18091886","article-title":"The Role of PALB2 in the DNA Damage Response and Cancer Predisposition","volume":"18","author":"Nepomuceno","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clon.2024.08.006_bib45","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/ng1942","article-title":"Fanconi anemia is associated with a defect in the BRCA2 partner PALB2","volume":"39","author":"Xia","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.clon.2024.08.006_bib46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/ng1959","article-title":"PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene","volume":"39","author":"Rahman","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.clon.2024.08.006_bib47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/jcp-2022-208461","article-title":"Gene of the month: PALB2","volume":"76","author":"Hamdan","year":"2023","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.clon.2024.08.006_bib48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13073-022-01052-8","article-title":"Breast cancer risks associated with missense variants in breast cancer susceptibility genes","volume":"14","author":"Dorling","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.clon.2024.08.006_bib49","article-title":"PALB2 and breast cancer: ready for clinical translation","volume":"43","author":"Southey","year":"2013","journal-title":"Appl Clin Genet"},{"key":"10.1016\/j.clon.2024.08.006_bib50","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa1400382","article-title":"Breast-Cancer Risk in Families with Mutations in PALB2","volume":"371","author":"Antoniou","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2024.08.006_bib51","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families","volume":"38","author":"Yang","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib52","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/ijc.32184","article-title":"Prevalence and clinical outcomes of germline mutations in BRCA1\/2 and PALB2 genes in 2769 unselected breast cancer patients in China","volume":"145","author":"Deng","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clon.2024.08.006_bib53","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1200\/JCO.22.01239","article-title":"Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2","volume":"41","author":"Yadav","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib54","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1158\/2159-8290.CD-16-1250","article-title":"Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1\/2 Mutations and Selected Sporadic Cancers","volume":"7","author":"de Bono","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clon.2024.08.006_bib55","article-title":"Association of Germline PALB2 Mutation and Response to Platinum-Based Chemotherapy in Metastatic Breast Cancer: A Case Series","volume":"1\u20135","author":"Isaac","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib56","doi-asserted-by":"crossref","first-page":"13150","DOI":"10.1093\/nar\/gku1065","article-title":"Chk2 and REG\u03b3-dependent DBC1 regulation in DNA damage induced apoptosis","volume":"42","author":"Magni","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.clon.2024.08.006_bib57","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1086\/373965","article-title":"Variants in CHEK2 Other than 1100delC Do Not Make a Major Contribution to Breast Cancer Susceptibility","volume":"72","author":"Schutte","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clon.2024.08.006_bib58","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2022.4071","article-title":"Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care\u2014Checking CHEK2","volume":"8","author":"Bychkovsky","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib59","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13058-016-0758-5","article-title":"Patient survival and tumor characteristics associated with CHEK2:p.I157T \u2013 findings from the Breast Cancer Association Consortium","volume":"18","author":"Muranen","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clon.2024.08.006_bib60","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/jmedgenet-2011-100380","article-title":"CHEK2\u22171100delC homozygosity is associated with a high breast cancer risk in women","volume":"48","author":"Adank","year":"2011","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.clon.2024.08.006_bib61","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2007.12.5922","article-title":"CHEK2 \u22171100delC Genotyping for Clinical Assessment of Breast Cancer Risk: Meta-Analyses of 26,000 Patient Cases and 27,000 Controls","volume":"26","author":"Weischer","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib62","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1200\/PO.19.00178","article-title":"Pathogenic Variants in CHEK2 Are Associated With an Adverse Prognosis in Symptomatic Early-Onset Breast Cancer","author":"Greville-Heygate","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib63","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1200\/JCO.2016.66.5844","article-title":"Age- and Tumor Subtype\u2013Specific Breast Cancer Risk Estimates for CH EK 2 \u22171100delC Carriers","volume":"34","author":"Schmidt","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib64","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1200\/JCO.2012.42.7336","article-title":"CHEK2 \u22171100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer\u2013Specific Death, and Increased Risk of a Second Breast Cancer","volume":"30","author":"Weischer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2018.11.005","article-title":"Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis","volume":"44","author":"Akdeniz","year":"2019","journal-title":"The Breast"},{"key":"10.1016\/j.clon.2024.08.006_bib66","doi-asserted-by":"crossref","first-page":"16142","DOI":"10.1002\/cam4.6272","article-title":"Association of the CHEK2 c. 1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival","volume":"12","author":"Morra","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.clon.2024.08.006_bib67","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.radonc.2006.12.002","article-title":"Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy","volume":"82","author":"Meyer","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib68","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/B:BREA.0000010697.49896.03","article-title":"Excess Risk for Contralateral Breast Cancer in CHEK2\u22171100delC Germline Mutation Carriers","volume":"83","author":"Broeks","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clon.2024.08.006_bib69","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00432-015-1981-7","article-title":"Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers","volume":"141","author":"Kriege","year":"2015","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib70","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/bjc.2014.306","article-title":"Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy","volume":"111","author":"Kriege","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2024.08.006_bib71","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes","volume":"38","author":"Tung","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib72","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10549-006-9406-6","article-title":"The role of ATM in breast cancer development","volume":"104","author":"Prokopcova","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clon.2024.08.006_bib73","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.2741\/4185","article-title":"Breast cancer genes: beyond BRCA1 and BRCA2","volume":"18","author":"Vega","year":"2013","journal-title":"Front Biosci"},{"key":"10.1016\/j.clon.2024.08.006_bib74","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/jmedgenet-2017-104588","article-title":"Rare, protein-truncating variants in ATM , CHEK2 and PALB2 , but not XRCC2 , are associated with increased breast cancer risks","volume":"54","author":"Decker","year":"2017","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.clon.2024.08.006_bib75","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/jmedgenet-2016-103839","article-title":"PALB2 , CHEK2 and ATM rare variants and cancer risk: data from COGS","volume":"53","author":"Southey","year":"2016","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.clon.2024.08.006_bib76","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","article-title":"Germline Pathogenic Variants in the Ataxia Telangiectasia Mutated (ATM) Gene are Associated with High and Moderate Risks for Multiple Cancers","volume":"14","author":"Hall","year":"2021","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.clon.2024.08.006_bib77","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/jnci\/djaa031","article-title":"Radiation Treatment, ATM , BRCA1\/2 , and CHEK2 \u22171100delC Pathogenic Variants and Risk of Contralateral Breast Cancer","volume":"112","author":"Reiner","year":"2020","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10.1016\/j.clon.2024.08.006_bib78","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/PO.20.00334","article-title":"Tolerability of Breast Radiotherapy Among Carriers of ATM Germline Variants","author":"Modlin","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib79","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.radonc.2022.09.007","article-title":"A\u00a0systematic review exploring the role of modern radiation for the treatment of Hereditary or Familial Breast Cancer","volume":"176","author":"Goel","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib80","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00140","article-title":"Cyclin-Dependent Kinase 4\/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair\u2013Related Genes","author":"Bruno","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib81","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0968-0004(98)01232-8","article-title":"Role of the human RAD51 protein in homologous recombination and double-stranded-break repair","volume":"23","author":"Baumann","year":"1998","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.clon.2024.08.006_bib82","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast Cancer Risk Genes \u2014 Association Analysis in More than 113,000 Women","volume":"384","author":"Dorling","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2024.08.006_bib83","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A\u00a0Population-Based Study of Genes Previously Implicated in Breast Cancer","volume":"384","author":"Hu","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2024.08.006_bib84","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/jmg-2022-108898","article-title":"UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C , RAD51D , BRIP1 and PALB2","volume":"60","author":"Hanson","year":"2023","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.clon.2024.08.006_bib85","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1093\/annonc\/mdy338","article-title":"Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1\/2-negative breast cancers","volume":"29","author":"Chen","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib87","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1200\/JCO.19.02859","article-title":"Genetic Factors in the Locoregional Management of Breast Cancer","volume":"38","author":"Haffty","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib88","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clon.2024.08.006_bib89","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nrm2395","article-title":"Transcriptional control of human p53-regulated genes","volume":"9","author":"Riley","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.clon.2024.08.006_bib90","first-page":"1233","article-title":"Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms","volume":"250","author":"Malkin","year":"1990","journal-title":"Science (1979)"},{"key":"10.1016\/j.clon.2024.08.006_bib91","first-page":"83","article-title":"Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers","volume":"10","author":"Nichols","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clon.2024.08.006_bib92","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1038\/s41388-021-01991-3","article-title":"Spontaneous and inherited TP53 genetic alterations","volume":"40","author":"Levine","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.clon.2024.08.006_bib93","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1002\/cncr.30248","article-title":"Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort","volume":"122","author":"Mai","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2024.08.006_bib94","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jmg.2010.078113","article-title":"A\u00a0novel HER2-positive breast cancer phenotype arising from germline TP53 mutations","volume":"47","author":"Wilson","year":"2010","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.clon.2024.08.006_bib95","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ijc.32424","article-title":"Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer","volume":"146","author":"Sheng","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clon.2024.08.006_bib96","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.breast.2022.07.002","article-title":"Risk of ipsilateral breast tumor recurrence and contralateral breast cancer in patients with and without TP53 variant in a large series of breast cancer patients","volume":"65","author":"Guo","year":"2022","journal-title":"The Breast"},{"key":"10.1016\/j.clon.2024.08.006_bib97","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3390\/cancers12020378","article-title":"Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer","volume":"12","author":"Hyder","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clon.2024.08.006_bib98","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1748-717X-5-104","article-title":"Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome","volume":"5","author":"Heymann","year":"2010","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib99","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10689-019-00153-5","article-title":"Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li\u2013Fraumeni syndrome)","volume":"19","author":"Petry","year":"2020","journal-title":"Fam Cancer"},{"key":"10.1016\/j.clon.2024.08.006_bib100","doi-asserted-by":"crossref","DOI":"10.2147\/BCTT.S134241","article-title":"Breast cancer in patients with Li\u2013Fraumeni syndrome \u2013 a case-series study and review of literature","volume":"9","author":"Nandikolla","year":"2017","journal-title":"Breast Cancer Targets Ther"},{"key":"10.1016\/j.clon.2024.08.006_bib101","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2024.08.006_bib102","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li\u2013Fraumeni and heritable TP53-related cancer syndromes","volume":"28","author":"Frebourg","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.clon.2024.08.006_bib103","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejca.2018.06.011","article-title":"Contribution of genotoxic anticancer treatments to the development of multiple primary tumors in the context of germline TP53 mutations","volume":"101","author":"Kasper","year":"2018","journal-title":"Eur J Cancer"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655524003194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655524003194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T17:14:46Z","timestamp":1748452486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655524003194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":100,"alternative-id":["S0936655524003194"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2024.08.006","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Impact of Constitutional Genomic Testing on Current Breast Cancer Care","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2024.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}],"article-number":"103631"}}